The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Project Orbis: Accelerating Global Access to Innovative Cancer Therapies
Read More
post
The Importance of Quality in Drug Development with Insights from the FDA Fiscal Year 2023 Report on the State of Pharmaceutical Quality
Read More
post
Why are Biologics Drugs Different
Read More
post
Why Hire an Experienced CMC Consultant for Your Early Phase Studies
Read More
Let's move from science to success.
Let’s Talk